FDA squashes accelerated hopes for Eli Lilly’s Alzheimer’s drug as agency asks for more data – Endpoints News

Endpoints founder John Carroll sat down with ARCH managing director Robert Nelsen during JP Morgan to talk about innovation, what’s getting funded and what’s ahead in 2023. This transcript has been edited for brevity and clarity.

John Carroll:

I’m here with Bob Nelsen, one of the co-founders of ARCH. Bob and I talk every now and then, usually about one of his latest crazy ideas that he’s invested a tremendous sum of money in. And I wanted to use this as an opportunity to talk about what he is about. Fascinating stuff. I did a little bit of research, not a lot, but I went back to Matt Herper’s article in 2016, when Leroy Hood described you as a genius at getting companies like Illumina started. And you’ve done a whole variety of different things. You were talking about getting involved in Alnylam, and you were talking about you being involved in Juno, one of the original CAR-T companies that was out there, Denali, Vir, Resilience today is in the news; Mubadala is financing a new manufacturing plant in the United Arab Emirates. Lots going on in what you could call a very interesting market, but I wanted to start back at the beginning, because I think that’s really cool. You got your MBA in 1986.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.


Leave a Comment

Your email address will not be published. Required fields are marked *

%d bloggers like this: